BNP Paribas Asset Management’s Travere Therapeutics TVTX Stock Holding History

BNP Paribas Asset Management’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$75.1K	Sell	1,322 -68	-5%	-$3.02K	﹤0.01%	1633
2026 Q1	$41.3K	Buy	1,390 +288	+26%	+$8.61K	﹤0.01%	1807
2025 Q4	$42K	Buy	1,102 +418	+61%	+$13.6K	﹤0.01%	1718
2025 Q3	$16K	Hold	684	–	–	﹤0.01%	1481
2025 Q2	$10K	Buy	+684	New	+$11.3K	﹤0.01%	1789
2016 Q1	–	Sell	-328,294	Closed	-$6.33M	–	1086
2015 Q4	$6.33M	Buy	328,294 +23,181	+8%	+$463K	0.05%	397
2015 Q3	$6.18M	Buy	305,113 +63,620	+26%	+$1.88M	0.05%	408
2015 Q2	$8.01M	Buy	+241,493	New	+$6.61M	0.06%	381

Other funds holding TVTX

Jupiter Topco New York $245B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BNP Paribas Asset Management's TVTX Position: Q2 2026 in Review

BNP Paribas Asset Management reduced its Travere Therapeutics (TVTX) stake by 4.9% in Q2 2026, selling an estimated $3.02K and leaving 1,322 shares worth $75.1K. The position accounts for ﹤0.01% of the portfolio, ranked #1633.

BNP Paribas Asset Management first reported a position in TVTX in Q2 2015 and has held it in 8 quarters since. The position peaked at $8.01M in Q2 2015. 321 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

BNP Paribas Asset Management held 1,322 shares of Travere Therapeutics worth $75.1K as of Q2 2026.
BNP Paribas Asset Management sold 68 Travere Therapeutics shares in Q2 2026, an estimated $3.02K.
Travere Therapeutics made up ﹤0.01% of BNP Paribas Asset Management's portfolio in Q2 2026, its #1633 holding.
BNP Paribas Asset Management first reported a position in Travere Therapeutics in Q2 2015 and has held it in 8 quarters since.
BNP Paribas Asset Management's Travere Therapeutics position peaked at $8.01M in Q2 2015.
321 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on BNP Paribas Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.